Filtered By:
Condition: Obesity
Drug: Clopidogrel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Which Antiplatelet Agent for Patients With TIA and Obesity? Which Antiplatelet Agent for Patients With TIA and Obesity?
Ticagrelor plus aspirin was associated with a lower risk for recurrent stroke than clopidogrel plus aspirin in patients with obesity who carry the CYP2C19 loss-of-function allele.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - July 12, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack
CMAJ. 2023 Jul 10;195(26):E897-E904. doi: 10.1503/cmaj.230262.ABSTRACTBACKGROUND: Body mass index (BMI) may affect the response to platelet P2Y12 receptor inhibitors. We aimed to explore whether BMI influenced the efficacy and safety of ticagrelor and clopidogrel for secondary prevention of minor ischemic stroke or transient ischemic attack (TIA) among patients enrolled in the CHANCE-2 (Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II) trial.METHODS: In a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, we randomized patients ...
Source: Canadian Medical Association Journal - July 10, 2023 Category: General Medicine Authors: Jia Zhang Anxin Wang Xue Tian Xia Meng Xuewei Xie Jing Jing Jinxi Lin Yilong Wang Zixiao Li Liping Liu Hao Li Yong Jiang Xingquan Zhao Yongjun Wang Source Type: research
Long-term risk, clinical management, and healthcare resource utilization of stable patients with coronary artery disease and post-myocardial infarction in Greece-TIGREECE study
CONCLUSIONS: Study results indicate that in the routine care of Greece one in ten patients experience a recurring CV event or death, mainly of ischemic origin, 1-3 years post-MI.PMID:36746373 | DOI:10.1016/j.hjc.2023.01.007
Source: Hellenic Journal of Cardiology - February 6, 2023 Category: Cardiology Authors: Filippos Anastasiadis Dimitrios Antoniadis Dimitrios Chountis Ioannis Mantas Ioannis Lekakis Moses Elisaf Charalampos Karvounis Athanasios Manolis Georgios Hahalis Ioannis Kogias Theodora Tourtoglou Dimitrios Gourlis Dimitrios Tsounis TIGREECE Study Inves Source Type: research
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
ConclusionsIn patients who receive clopidogrel after PCI, concomitant use of PPI seems to increase the risk of major cardiovascular events.
Source: Cardiovascular Drugs and Therapy - November 11, 2022 Category: Cardiology Source Type: research
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research
